Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim to make investment in Eyevensys

Boehringer Ingelheim to make investment in Eyevensys

18th April 2013

Boehringer Ingelheim has announced it is making an investment in the ocular health-focused company Eyevensys through its Boehringer Ingelheim Venture Fund.

An injection of funding will support Eyevensys' work in developing a new process for non-viral gene therapy using electrotransfer, which enables prolonged production of therapeutic proteins for the treatment of ocular disease.

It is thought that this new approach will be less invasive than current therapies, as the frequency of injections can be reduced from fortnightly or monthly to twice a year, while also offering better efficacy and fewer side effects.

In addition to this investment, Boehringer Ingelheim's head of non-clinical research and development Dr Michel Pairet is joining the Eyevensys board of directors.

Dr Pairet said: "Eyevensys' novel approach, which targets pathologies where few therapies are available and offers potential advantages in terms of effectiveness, administration and tolerability, makes it a perfect fit with the Boehringer Ingelheim fund's criteria for investment."

Last month, the company announced the initiation of a new study of its diabetes therapy Trajenta, in association with partner Lilly.ADNFCR-8000103-ID-801573350-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.